A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68)

Official Title

A Phase 2 Study of Pembrolizumab (MK-3475) Every 6 Weeks (Q6W) in Participants With Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)

Summary:

The primary objective of the study is to evaluate the objective response rate (ORR), by cohort, rrcHL and rrPMBCL, as assessed by the investigator according to Lugano classification criteria 2014 in participants treated with pembrolizumab Q6W.

Trial Description

Primary Outcome:

  • Objective Response Rate (ORR) per Lugano Classification as Assessed by Investigator
Secondary Outcome:
  • Duration of Response (DOR) per Lugano Classification as Assessed by Investigator
  • Area Under the Curve (AUC) of Pembrolizumab
  • Maximum Serum Concentration (Cmax) of Pembrolizumab
  • Minimum Serum Concentration (Cmin) of Pembrolizumab
  • Antidrug Antibody Levels (ADA) for Pembrolizumab
  • Number of Participants Who Experienced an Adverse Event (AE)
  • Number of Participants Who Discontinued Study Treatment Due to AE

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society